Lugano, Switzerland (ots) - Helsinn Healthcare SA, a Swiss pharmaceutical group, is pleased to announce, ahead of schedule, today's launch in the UK of Aloxi® (Palonosetron hydrochloride), a new generation treatment for chemotherapy induced nausea and vomiting, by its local partner Maelor plc, the specialist hospital medicines group. Aloxi® is a patented ...
Indianapolis (ots/PRNewswire) - - Global contest seeks expressions of the triumphs and challenges of living with diabetes through art, essay, poetry, photography and music Eli Lilly and Company, the International Diabetes Federation (IDF), and the International Society for Pediatric and ...
Geneva (ots/PRNewswire) - Acrongenomics, Inc. (OTC: AGNM) is pleased to announce that they have acquired a 10.9% interest in Molecular Vision Limited, on a fully diluted basis. The cash consideration will be used by Molecular Vision for working capital and to further develop its technology. Molecular Vision is developing low cost easy-to-use credit-card sized devices for medical testing that will greatly extend ...
San Antonio, Texas (ots/PRNewswire) - - New Findings From a Second Pivotal Phase 3 Study Show Subjects Receiving Ustekinumab Every 12 weeks Maintained Improvement From Psoriasis Through One Year One-year data from the second double blind, placebo-controlled Phase 3 study PHOENIX 1 showed therapy with ...
Basel, Switzerland (ots/PRNewswire) - - Many More Patients Can Now Benefit From Oral Chemotherapy That Significantly Reduces Treatment Time Roche announced today that the European Commission has approved its oral chemotherapy Xeloda (capecitabine) for the treatment of metastatic colorectal cancer in combination with any chemotherapy in all lines of ...
Abbott Park, Illinois (ots/PRNewswire) - - Improved Medical Benefit Rating Granted for XIENCE V from French Health Authority Abbott (NYSE: ABT) today announced that it has received reimbursement approval in France for its XIENCE(TM) V Everolimus Eluting Coronary Stent System, the first drug eluting stent to demonstrate clinical superiority over another drug ...
Maidenhead, England (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that the European Medicines Agency (EMEA) has validated the marketing authorisation application for Torisel(R) (temsirolimus) for treating relapsed and/or refractory mantle cell lymphoma (MCL), a rare type of non-Hodgkin's lymphoma (NHL) that accounts for ...
Abbott Park, Illinois (ots/PRNewswire) - - Lopinavir/ritonavir tablet is the first and only co-formulated protease inhibitor tablet approved for use in children with HIV Abbott (NYSE: ABT) announced today that the European Committee for Medicinal Products for Human Use (CHMP), the scientific committee ...
Paris (ots/PRNewswire) - Sanofi-aventis announced today that the anticoagulant Clexane(R) (enoxaparin sodium injection) has been approved for marketing in Japan by the Ministry of Health, Labour and Welfare for the prevention of venous thromboembolism (VTE) in patients undergoing orthopaedic surgery of the lower limbs such as total hip replacement, total knee replacement and hip fracture surgery. Venous ...
Basel, Switzerland (ots/PRNewswire) - - Avastin Receives Broad Label Extension in Europe for the Treatment of Patients With Metastatic Colorectal Cancer Roche announced today that the European Commission (EC) has given its approval for the significantly wider use of its anti-angiogenic agent Avastin (bevacizumab) in patients suffering from ...
European Influenza Surveillance Scheme (EISS)
Utrecht, The Netherlands and Stockholm, Sweden (ots/PRNewswire) - The 'flu' has arrived in Europe, according to the European Influenza Surveillance Scheme (EISS) and the European Centre for Disease Prevention and Control (ECDC). The two organisations confirm an upsurge in the number of laboratory confirmed cases of influenza in several European countries. As of this week, 13 European countries are reporting significant influenza activity (Austria, Bulgaria, France, ...
Mississauga, Canada (ots/PRNewswire) - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) today announced that The Lancet, a world-leading medical journal, will publish an article entitled 'Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial' in its January 19th issue (Lancet 2008; 371: 228-36). The article describes the results from Vasogen's ...
Evry, France (ots/PRNewswire) - - Not for Distribution in the United States, Canada or Japan Novagali Pharma, an emerging ophthalmic pharmaceutical company announced today that the Company's Investigational New Drug Application (IND) to conduct a Phase I clinical trial of its Nova63035, an ophthalmic ...
Hoofddorp, The Netherlands (ots/PRNewswire) - CEVA Logistics, the 4th largest supply chain company worldwide, has appointed Peter Dew as Group Chief Information Officer (CIO), effective April 1, 2008. He will be responsible for establishing and implementing CEVA's IT strategy at a global level. Peter Dew has a wealth of experience from similar roles in major international corporations. Prior to joining CEVA, he was ...
London (ots/PRNewswire) - AstraZeneca (LSE: AZN) (NYSE: AZN) today announced the launch of a new clinical trial, SATURN, designed to measure the impact of CRESTOR(TM) (rosuvastatin) 40 mg and atorvastatin (Lipitor(R)) 80 mg on the progression of atherosclerosis in high risk patients. SATURN will compare ...
Basel, Switzerland (ots/PRNewswire) - Following an announcement from Schering-Plough, Roche today affirmed the value of PEGASYS(R) (peginterferon alfa-2a) in combination with COPEGUS(R) (Roche's brand of ribavirin) as the market-leading treatment for patients with hepatitis C. Despite clear biases in the design of the "IDEAL" study that potentially favoured patients taking PegIntron(TM) (peginterferon alfa-2b) regimens ...
Calgary, Canada (ots/PRNewswire) - - Resverlogix Sees Early Success and Expedites Phase 2 Plans TSX Exchange Symbol: RVX Resverlogix is pleased to announce preliminary data from the RVX-208 Phase 1 safety and pharmacokinetics study. Forty healthy volunteers have so far been treated of which sixteen have received multiple doses. As anticipated from the extensive Investigational New Drug toxicology studies no ...
Nairobi (ots/PRNewswire) - cbm through its staff and Regional Office in Nairobi is providing emergency assistance to the humanitarian crisis in Kenya. It is estimated that around 500,000 people have lost their homes, due to the widespread violence following the disputed election. Prof. Allen Foster, cbm's President announced, "There is an urgent need of food, shelter and health services, and cbm will ...
Basel, Switzerland (ots/PRNewswire) - - For non US or non UK Media Only - Oral Chemotherapy Tablet Option Reduces the Time Patients Need to Spend in the Hospital Data recently published in the New England Journal of Medicine confirm oral chemotherapy tablet Xeloda (capecitabine) as a first-line ...
Toronto (ots/PRNewswire) - - President of cbm, Prof. Allen Foster Announces That cbm Has Expanded its Areas of Work to Include All Persons With Disability, Not Just Persons With Visual Loss. For the past 100 years, cbm previously known as Christoffel Blinden Mission, and Christian Blind Mission, has worked to prevent and treat blindness and provide education and rehabilitation services for persons with visual loss. "The organization has decided that its ...
Lyon, France (ots/PRNewswire) - - Exclusive Agreement for Rabies Monoclonal Antibodies to Fight Fatal Disease Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has signed an exclusive collaboration and commercialization agreement with Crucell N.V. (Euronext, NASDAQ: CRXL) for Crucell's rabies monoclonal antibodies ...
Malvern, Pennsylvania (ots/PRNewswire) - Solstice Neurosciences, Inc. ("Solstice") announced the appointment of Dennis L. Smith as President and Chief Executive Officer. He will also continue to serve as Chairman to its Board of Directors. Mr. Smith brings unique specialty pharmaceutical ...
Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Canada (ots/PRNewswire) - The Centre hospitalier de l'Université de Montréal (CHUM) announces the beginning of a phase II randomized double-blind trial with the potential of providing a therapeutic alternative after a first acute myocardial infarction. One patient has already undergone this technique, ...
Basel (ots/PRNewswire) - - Avastin Offers Patients the Chance to Live Twice as Long Without Their Disease Advancing Avastin (bevacizumab), Roche's innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced renal cell cancer (RCC) in combination with interferon (IFN), the current standard of care[*]. ...
Mississauga, Canada (ots/PRNewswire) - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) and Grupo Ferrer Internacional, S.A. ("Ferrer"), a leading European pharmaceutical and medical devices company, today announced the receipt of initial orders for Vasogen's Celacade(TM) System in Germany. Celacade, a first-in-class therapy, is the only CE Mark approved product that ...
Siemens Medical Solutions Diagnostics
Deerfield, Illinois (ots/PRNewswire) - - Third-Generation TRAb Assay Delivers Unprecedented Specificity for Diagnosing Graves' Disease Siemens Medical Solutions Diagnostics (www.siemens.com/diagnostics) announced that it has signed an agreement with KreLo GmbH Medical Diagnostics for the rights to develop ...
San Antonio, Texas (ots/PRNewswire) - - Roche in Collaboration With Genentech Commit to Large Phase III Adjuvant Clinical Programme Set to Unlock Avastin's Potential in Early Breast Cancer According to new phase II study data, Avastin (bevacizumab) can proceed to be tested after breast cancer surgery in combination with anthracycline containing regimens. ...
San Antonio, Texas (ots/PRNewswire) - - Studies Show Breast Cancer Patients Benefit From Continued Use of Herceptin After Progression of the Disease Data presented at the 30th Annual San Antonio Breast Cancer Symposium confirm that Herceptin is the standard of care for women with HER2-positive breast ...
San Antonio, Texas (ots/PRNewswire) - New data presented today at the San Antonio Breast Cancer Symposium (SABCS) show that adding Xeloda (capecitabine) to the current gold standard combination of Herceptin (trastuzumab) and docetaxel allows patients with advanced HER2-positive breast cancer to live, on average 5 ...
Basel, Switzerland (ots/PRNewswire) - - Physicians Will be Able to Prescribe MabThera With Their Preferred Chemotherapy Regimen as Initial Treatment Roche announced today that the European Union's Committee on Human Medical Products (CHMP) has given a positive recommendation for extension of the MabThera ...